RCS - Celadon Pharma. PLC - Investor Site Visit – Tuesday 22 October 2024

Celadon PharmaceuticalsAnnouncement

04/10/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD0375Ha&default-theme=true

RNS Number : 0375H  Celadon Pharmaceuticals PLC  04 October 2024

Celadon Pharmaceuticals Plc

("Celadon" or the "Group")

Investor Site Visit - Tuesday 22(nd) October 2024

4(th) October 2024 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing,
and sale of breakthrough cannabis-based medicines, is pleased to extend an
invitation for new and existing shareholders to visit our cultivation and
manufacturing facility in the West Midlands on 22 October 2024, organised by
Global Investment Strategy UK Ltd.

James Short, Chief Executive Officer of Celadon, will take investors on a
walkthrough tour of the Group's 100,000 sq ft facility which will be followed
up with a presentation and the opportunity for Q&A. A light lunch and
drinks will be provided.

Further details regarding location and time will be provided once investors
have registered their interest, and relevant non-disclosure agreements have
been signed. To register your interest for this event please click on the
following link and fill out your details in the form provided;
https://celadonpharma.com/investor-site-visit/
(https://celadonpharma.com/investor-site-visit/)

 

 Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                                                                    Via Sodali & Co

 Jonathan Turner

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts                                                                  +44 (0)20 7523 8000

 Global Investment Strategy UK Limited (Joint Broker)                                           +44 (0)20 7048 9400

 James Sheehan

 Sodali & Co
 Elly Williamson / Sam Austrums / Nick Johnson                                                  +44 (0)20 7250 1446

 

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain sufferers,
as well as exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved
and comprises indoor hydroponic cultivation, proprietary GMP extraction and an
analytical and R&D laboratory. Celadon's Home Office licence allows for
the commercial supply of its pharmaceutical-grade cannabis product. The Group
owns an approved clinical trial using cannabis-based medicinal products to
treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a licensed
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication
of this announcement, this information is now considered to be in the public
domain.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSLIVLSIIS